Systemic drug-induced chronic paronychia and periungual pyogenic granuloma

Wollina, Uwe

doi:10.4103/idoj.idoj_133_18

Cited by 16 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 47 ] Several drugs [ Table 4 ] have been known to cause CP or a delayed complication such as periungual pyogenic granuloma. [ 4 48 49 50 51 ] Mechanisms include an increase in the retinoic acid concentrations and inhibition of EGFR. [ 2 52 ] Pemphigus [ Figure 7 ], psoriasis [ Figure 8 ] and reactive arthritis may also present with CP, although presentation as AP is more common.…”

Section: Hronic P Aronychiamentioning

confidence: 99%

Acute and chronic paronychia revisited: A narrative review

Relhan¹,

Bansal²

2022

J Cutan Aesthet Surg

View full text Add to dashboard Cite

Paronychia refers to the inflammation of the tissue which immediately surrounds the nail and it can be acute (<6 weeks duration) or chronic (>6 weeks duration). Disruption of the protective barrier between the nail plate and the adjacent nail fold preceded by infectious or noninfectious etiologies results in the development of paronychia. A combination of general protective measures, and medical and/or surgical interventions are required for management. This review explores the pathogenesis, clinical features, differential diagnosis, medical, and surgical management of paronychia. For the purpose of this review, we searched the PubMed, Cochrane, and Scopus databases using the following keywords, titles, and medical subject headings (MeSH): acute paronychia, chronic paronychia, and paronychial surgeries. Relevant review articles, original articles, and case reports/series published till February 2020 were included in this study.

show abstract

Section: Hronic P Aronychiamentioning

confidence: 99%

Acute and chronic paronychia revisited: A narrative review

Relhan¹,

Bansal²

2022

J Cutan Aesthet Surg

View full text Add to dashboard Cite

show abstract

“…Epidermal growth factor receptor inhibitors [3][4][5][6] Cetuximab Panitumumab Erlotinib Gefitinib Osimertinib…”

Section: Ibrutinibmentioning

confidence: 99%

“…Taxanes 4 Docetaxel Paclitaxel VEGFR inhibitors 4 Bevacizumab FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; mTOR, mechanistic target of rapamycin; MEK, mitogen-activated protein kinase kinase; VEGFR, vascular endothelial growth factor receptor.…”

Section: Ibrutinibmentioning

confidence: 99%

“…Drug-induced paronychia is a common toxicity in targeted anticancer therapies such as epidermal growth factor receptor inhibitors (EGFRis), mitogen-activated protein kinase kinase (MEK) inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, and phosphatidylinositol-3-kinase inhibitors (PI3Kis) (Table 1). 2–10 Epidermal growth factor receptor inhibitors inhibit typical pathways involved in epithelial maturation leading to instability and inflammation of periungual tissue. 11 Based on a previous meta-analysis, EGFRi treatment led to nail toxicities in 17.2% of patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies

et al. 2021

View full text Add to dashboard Cite

BACKGROUND Paronychia is a common toxicity associated with targeted anticancer therapies. Antibiotics and steroids are the standard treatments for severe paronychia, yet they are often inadequate, prolonging the patient's suffering and resulting in changes to effective cancer therapy. OBJECTIVE This article describes the clinical course of drug-induced paronychia and attempts to identify circumstances under which nail surgery may be beneficial. MATERIALS AND METHODS This is a retrospective case series from a single institution's electronic medical record for patients on paronychia-inducing anticancer therapies with nail disease visit diagnosis codes. RESULTS The authors identified 36 nail procedures performed on 12 patients, all of whom were managed with conservative steroid and antibiotic therapy with varying degrees of improvement; however, no further improvement was seen after 90 days. Partial matricectomy, nail avulsion, debridement/clipping, and incision and drainage were performed with resolution rates of 100% (11/11), 38.5% (5/13), 12.5% (1/8), and 0% (0/4), respectively. The average time to surgical intervention was 196 days, and the average time to resolution was 268 days. CONCLUSION This series highlights the prolonged course of severe drug-induced paronychia and the importance of surgical intervention to reduce pain and impact on cancer treatment. Partial matricectomy should be considered for paronychia unresponsive to conservative therapy by 3 months.

show abstract

“…Cause may be infective, traumatic, exposure to chemical irritant, or systemic drug-induced. 1 2 3 4 5 6 7 Patients with short duration present with acute paronychia, and when duration of paronychia is more than 6 weeks, it proceeds to chronic stage of inflammation. It is found in housewives and housemaids and also male labor class, with prolong repeated exposure to water and irritant chemical and other pollutants.…”

Section: Introductionmentioning

confidence: 99%

Chronic Paronychia of Great Toe Treated with Excision of Nail Plate along with Surrounding Tissue and Split Thickness Skin Graft: An Observational Prospective Study

Panda

2021

International Journal of Recent Surgical and Medical Sciences

View full text Add to dashboard Cite

Paronychia is an inflammatory condition of alongside of nail of toe or finger. It is seen commonly in housewives and housemaids. Paronychia may be acute or chronic. Majority of patients with acute paronychia respond well to nonsurgical treatment. Patients with chronic paronychia of great toe do not respond to nonsurgical treatment. Patients suffer from chronic pain in finger or toe. Many treatment methods are available for chronic paronychia of great toe. All have merits, demerits, and different outcomes. This study is conducted to find out the outcome of a modified surgical technique in chronic paronychia of great toe of patients. This is a method adopted with a little modification of existing method.This study was conducted among 50 patients of chronic paronychia of great toe, who were between 15 to 55 years of age, from December 2019 to December 2020. These patients were operated and kept on follow-up for 1 year and observed for different outcomes likes skin graft take off, complete wound healing of operated area, relief from chronic pain of great toe, acceptance of cosmetic appearance, and recurrence of disease. Clinical data was recorded in case record form by examining the patient, asking questions to them, and conducting descriptive analysis. Results in terms of skin graft take off, complete wound healing of operated area, relief from chronic pain of great toe, acceptance of cosmetic appearance, and recurrence of disease were assessed during follow-up period. Postoperative result showed that 98% of patients had complete wound healing and complete graft take up, acceptance of cosmetic appearance was 94%, recurrence was 2%, and 90% were relieved from chronic pain of disease great toe. It was concluded that this was a better method for treatment of chronic paronychia of great toe.

show abstract

Systemic drug-induced chronic paronychia and periungual pyogenic granuloma

Cited by 16 publications

References 43 publications

Acute and chronic paronychia revisited: A narrative review

Acute and chronic paronychia revisited: A narrative review

Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies

Chronic Paronychia of Great Toe Treated with Excision of Nail Plate along with Surrounding Tissue and Split Thickness Skin Graft: An Observational Prospective Study

Contact Info

Product

Resources

About